Aerosomes myocardial contrast echocardiography (MCE) accurately detects resting myocardial perfusion abnormalities post myocardial infarction

Edward W. Gertz, Pete Manspeaker, Thomas Fritz, Sanjiv Kaul, Evan Unger

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A multicenter, Phase II, myocardial perfusion study with Aerosomes (phospholipid coated, perfluropropane/air containing microbubbles) was performed to evaluate safety and efficacy in patients post Q wave myocardial infarction (MI). Seventeen patients, 4 days to 6 months post Q wave MI received IV bolus injections of Aerosomes and were imaged at end systole (ES) utilizing second harmonic technique. SPECT 99mTc Sestamibi nuclear scans were performed ±72 hours of the MCE study. Serial vital signs, 12 lead ECGs, urinalysis, hematology and blood chemistries were performed to 72 hours post MCE study. Composite, processed, ES ultrasound images were compared to the blinded readings of the 99mTc Sestamibi images on a segment to segment basis. The population consisted of 13 males and 4 females with a mean age of 64.7±11.4 years. No serious adverse events occurred. There were no clinically significant vital sign, ECG, urine, hematology, or blood chemistry changes attributed to Aerosomes administration. Compared to the 99mTc Sestamibi images, the MCE images with Aerosomes had a 92% sensitivity and a 87% specificity. A paired sign test comparing the two methods, yielded no significant difference between the methods. Aerosomes can accurately characterize myocardial perfusion comparable to 99mTc Sestamibi inpatients with previous Q wave myocardial infarction.

Original languageEnglish (US)
JournalUltrasound in Medicine and Biology
Volume23
Issue numberSuppl 1
StatePublished - 1997
Externally publishedYes

Fingerprint

myocardial infarction
Technetium Tc 99m Sestamibi
echocardiography
abnormalities
Echocardiography
hematology
Perfusion
systole
Myocardial Infarction
Vital Signs
Systole
Hematology
blood
urinalysis
Electrocardiography
chemistry
Microbubbles
Urinalysis
urine
Single-Photon Emission-Computed Tomography

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Aerosomes myocardial contrast echocardiography (MCE) accurately detects resting myocardial perfusion abnormalities post myocardial infarction. / Gertz, Edward W.; Manspeaker, Pete; Fritz, Thomas; Kaul, Sanjiv; Unger, Evan.

In: Ultrasound in Medicine and Biology, Vol. 23, No. Suppl 1, 1997.

Research output: Contribution to journalArticle

@article{8faf9ace84c34f8cb57809417c2b2063,
title = "Aerosomes myocardial contrast echocardiography (MCE) accurately detects resting myocardial perfusion abnormalities post myocardial infarction",
abstract = "A multicenter, Phase II, myocardial perfusion study with Aerosomes (phospholipid coated, perfluropropane/air containing microbubbles) was performed to evaluate safety and efficacy in patients post Q wave myocardial infarction (MI). Seventeen patients, 4 days to 6 months post Q wave MI received IV bolus injections of Aerosomes and were imaged at end systole (ES) utilizing second harmonic technique. SPECT 99mTc Sestamibi nuclear scans were performed ±72 hours of the MCE study. Serial vital signs, 12 lead ECGs, urinalysis, hematology and blood chemistries were performed to 72 hours post MCE study. Composite, processed, ES ultrasound images were compared to the blinded readings of the 99mTc Sestamibi images on a segment to segment basis. The population consisted of 13 males and 4 females with a mean age of 64.7±11.4 years. No serious adverse events occurred. There were no clinically significant vital sign, ECG, urine, hematology, or blood chemistry changes attributed to Aerosomes administration. Compared to the 99mTc Sestamibi images, the MCE images with Aerosomes had a 92{\%} sensitivity and a 87{\%} specificity. A paired sign test comparing the two methods, yielded no significant difference between the methods. Aerosomes can accurately characterize myocardial perfusion comparable to 99mTc Sestamibi inpatients with previous Q wave myocardial infarction.",
author = "Gertz, {Edward W.} and Pete Manspeaker and Thomas Fritz and Sanjiv Kaul and Evan Unger",
year = "1997",
language = "English (US)",
volume = "23",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "Suppl 1",

}

TY - JOUR

T1 - Aerosomes myocardial contrast echocardiography (MCE) accurately detects resting myocardial perfusion abnormalities post myocardial infarction

AU - Gertz, Edward W.

AU - Manspeaker, Pete

AU - Fritz, Thomas

AU - Kaul, Sanjiv

AU - Unger, Evan

PY - 1997

Y1 - 1997

N2 - A multicenter, Phase II, myocardial perfusion study with Aerosomes (phospholipid coated, perfluropropane/air containing microbubbles) was performed to evaluate safety and efficacy in patients post Q wave myocardial infarction (MI). Seventeen patients, 4 days to 6 months post Q wave MI received IV bolus injections of Aerosomes and were imaged at end systole (ES) utilizing second harmonic technique. SPECT 99mTc Sestamibi nuclear scans were performed ±72 hours of the MCE study. Serial vital signs, 12 lead ECGs, urinalysis, hematology and blood chemistries were performed to 72 hours post MCE study. Composite, processed, ES ultrasound images were compared to the blinded readings of the 99mTc Sestamibi images on a segment to segment basis. The population consisted of 13 males and 4 females with a mean age of 64.7±11.4 years. No serious adverse events occurred. There were no clinically significant vital sign, ECG, urine, hematology, or blood chemistry changes attributed to Aerosomes administration. Compared to the 99mTc Sestamibi images, the MCE images with Aerosomes had a 92% sensitivity and a 87% specificity. A paired sign test comparing the two methods, yielded no significant difference between the methods. Aerosomes can accurately characterize myocardial perfusion comparable to 99mTc Sestamibi inpatients with previous Q wave myocardial infarction.

AB - A multicenter, Phase II, myocardial perfusion study with Aerosomes (phospholipid coated, perfluropropane/air containing microbubbles) was performed to evaluate safety and efficacy in patients post Q wave myocardial infarction (MI). Seventeen patients, 4 days to 6 months post Q wave MI received IV bolus injections of Aerosomes and were imaged at end systole (ES) utilizing second harmonic technique. SPECT 99mTc Sestamibi nuclear scans were performed ±72 hours of the MCE study. Serial vital signs, 12 lead ECGs, urinalysis, hematology and blood chemistries were performed to 72 hours post MCE study. Composite, processed, ES ultrasound images were compared to the blinded readings of the 99mTc Sestamibi images on a segment to segment basis. The population consisted of 13 males and 4 females with a mean age of 64.7±11.4 years. No serious adverse events occurred. There were no clinically significant vital sign, ECG, urine, hematology, or blood chemistry changes attributed to Aerosomes administration. Compared to the 99mTc Sestamibi images, the MCE images with Aerosomes had a 92% sensitivity and a 87% specificity. A paired sign test comparing the two methods, yielded no significant difference between the methods. Aerosomes can accurately characterize myocardial perfusion comparable to 99mTc Sestamibi inpatients with previous Q wave myocardial infarction.

UR - http://www.scopus.com/inward/record.url?scp=0030651550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030651550&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030651550

VL - 23

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - Suppl 1

ER -